^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

    Excerpt:
    ...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

    Excerpt:
    ...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    EACR 2021
    Title:

    Metabolic adaptation of BRAF-driven papillary thyroid carcinomas is attenuated by vemurafenib and diclofenac combination

    Published date:
    05/28/2020
    Excerpt:
    ...BRAF-mutated PTC cell lines were used to validate the effects of single and combined (VMR plus diclofenac) treatments…BRAF-mutant PTCs can be successfully treated with a new drug combination, which provides a new potential option even for drug-resistant BRAF-driven carcinomas.